Literature DB >> 7495996

In vitro antimycobacterial activity of a new quinolone, levofloxacin (DR-3355).

H Saito1, K Sato, H Tomioka, S Dekio.   

Abstract

OBJECTIVE: To examine in vitro antimycobacterial activity of levofloxacin.
DESIGN: Minimum inhibitary concentrations (MICs) of levofloxacin for various mycobacterial species were determined by the agar dilution method using 7H11 medium and compared with those of ofloxacin. Antimicrobial activity of levofloxacin against Mycobacterium tuberculosis and M. intracellulare phagocytosed in murine peritoneal macrophages was measured in terms of reducing cell-associated bacterial colony forming units (CFUs).
RESULTS: MICs of levofloxacin against M. tuberculosis, M. kansasii, M. marinum, M. scrofulaceum, M. avium, M. intracellulare, M. fortuitum, and M. chelonae were 2 to 4 times lower than those of ofloxacin. Levofloxacin exhibited higher efficacy in reducing bacterial CFUs in macrophages than ofloxacin.
CONCLUSION: Levofloxacin possessed more potent in vitro antimycobacterial activities as compared to that of ofloxacin.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7495996     DOI: 10.1016/0962-8479(95)90001-2

Source DB:  PubMed          Journal:  Tuber Lung Dis        ISSN: 0962-8479


  11 in total

1.  Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.

Authors:  H Tomioka; K Sato; H Kajitani; T Akaki; S Shishido
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

Review 2.  Future directions in the development of new antitubercular drugs. Where do we go from here?

Authors:  W W Yew; C H Chau
Journal:  Drugs Aging       Date:  1997-06       Impact factor: 3.923

3.  Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.

Authors:  H Tomioka; K Sato; T Akaki; H Kajitani; S Kawahara; M Sakatani
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

Review 4.  Activity of quinolones against mycobacteria.

Authors:  M R Jacobs
Journal:  Drugs       Date:  1999       Impact factor: 9.546

Review 5.  Treatment and prevention of multidrug-resistant tuberculosis.

Authors:  I Bastian; R Colebunders
Journal:  Drugs       Date:  1999-10       Impact factor: 9.546

Review 6.  The role of fluoroquinolones in tuberculosis today.

Authors:  S E Berning
Journal:  Drugs       Date:  2001       Impact factor: 9.546

7.  Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine.

Authors:  N Rastogi; K S Goh; A Bryskier; A Devallois
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

8.  In vitro activities of levofloxacin used alone and in combination with first- and second-line antituberculous drugs against Mycobacterium tuberculosis.

Authors:  N Rastogi; K S Goh; A Bryskier; A Devallois
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

9.  Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates.

Authors:  Augustine F B Cheng; Wing W Yew; Edward W C Chan; Miu L Chin; Mamie M M Hui; Raphael C Y Chan
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

10.  In vivo efficacy of ABT-255 against drug-sensitive and -resistant Mycobacterium tuberculosis strains.

Authors:  A Oleksijew; J Meulbroek; P Ewing; K Jarvis; M Mitten; L Paige; A Tovcimak; M Nukkula; D Chu; J D Alder
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.